What precautions should be taken when prescribing prednisone?

Precautions During Prednisone Therapy

Prednisone requires careful monitoring for infection risk, adrenal suppression, metabolic complications, and gastrointestinal protection, with dosing timing and tapering protocols being critical to minimize toxicity while maintaining therapeutic benefit.

Infection Risk and Immunosuppression

• Screen for latent tuberculosis before initiating prednisone, as corticosteroids can reactivate dormant TB infection; patients with latent TB or tuberculin reactivity should receive chemoprophylaxis during prolonged therapy 1.

• Avoid exposure to varicella (chickenpox) and measles in non-immune patients taking prednisone, as these infections can have serious or fatal courses; if exposure occurs, prophylaxis with varicella zoster immune globulin or measles immunoglobulin may be indicated 1.

• Screen for hepatitis B infection before starting immunosuppressive doses of prednisone, as viral reactivation can occur even in patients with apparently resolved hepatitis B; consultation with hepatology specialists is recommended for positive cases 1.

• Rule out latent amebiasis and Strongyloides (threadworm) infestation before initiating prednisone in patients who have spent time in the tropics or have unexplained diarrhea, as corticosteroid-induced immunosuppression can lead to life-threatening disseminated infections 1.

• Avoid prednisone in the presence of systemic fungal infections unless needed to control drug reactions; for patients on chronic therapy who develop fungal infections, consider dose reduction or withdrawal 1.

• Provide pneumocystis prophylaxis with trimethoprim-sulfamethoxazole when prednisone exceeds 30 mg/day for more than 3 weeks 2.

Adrenal Suppression and Stress Dosing

• Anticipate hypothalamic-pituitary-adrenal (HPA) axis suppression in any patient receiving >7.5 mg/day for >3 weeks, as this threshold consistently produces adrenal suppression that may persist for up to 12 months after discontinuation 3, 4, 1.

• Increase prednisone dosage during periods of unusual stress (surgery, severe infection, trauma) before, during, and after the stressful situation; patients on chronic therapy require supplemental glucocorticoids such as hydrocortisone 50-100 mg three times daily for major physiologic stress 3, 1.

• Provide patients with written stress-dosing instructions and ensure they carry an emergency glucocorticoid supply or medical alert bracelet identifying them as at risk for adrenal insufficiency 3.

• Never abruptly discontinue prednisone after prolonged therapy, as adrenocortical insufficiency may result; gradual dose reduction is mandatory, typically tapering by 1 mg every 4 weeks once the dose reaches ≤10 mg/day 3, 1.

Optimal Dosing Timing

• Administer the entire daily prednisone dose as a single morning dose before 9 AM to align with physiologic cortisol rhythms and minimize HPA-axis suppression, as maximal adrenal cortex activity occurs between 2 AM and 8 AM 3, 1, 5.

• Avoid divided daily doses except in special situations such as prominent night pain while on low doses (<5 mg daily), as single morning dosing is superior for reducing adrenal suppression 3, 1.

Gastrointestinal Protection

• Prescribe a proton pump inhibitor for gastric protection throughout corticosteroid therapy, particularly when prednisone is combined with NSAIDs or when doses exceed moderate levels 2.

• Reduce gastric irritation by taking prednisone before, during, or immediately after meals or with food or milk 1.

• Consider administering antacids between meals when large doses are given to help prevent peptic ulcers 1.

Bone Health Monitoring

• Initiate calcium supplementation (800-1,000 mg/day) and vitamin D (400-800 units/day) at the start of prednisone therapy to prevent corticosteroid-induced osteoporosis 4, 6, 7.

• Perform DEXA bone scans at 1-2 year intervals in patients on long-term steroid therapy to monitor bone density 4.

• Recognize that all corticosteroids increase calcium excretion, contributing to bone loss over time 1.

Cardiovascular and Metabolic Monitoring

• Monitor blood pressure, serum sodium, and potassium regularly, as prednisone can cause salt and water retention, hypertension, and increased potassium excretion; dietary salt restriction and potassium supplementation may be necessary 3, 1.

• Use prednisone with great caution in patients with recent myocardial infarction, as literature reports suggest an association between corticosteroid use and left ventricular free wall rupture 1.

• Monitor blood glucose levels, particularly in diabetic patients or those at risk, as prednisone causes dose-dependent hyperglycemia 8.

• Screen for mood changes and psychiatric symptoms, as prednisone can induce depression, anxiety, and other neuropsychiatric effects; consider dose reduction when feasible if these symptoms emerge 3.

Dose-Specific Precautions

• Classify doses as low (<7.5 mg/day), medium (7.5-30 mg/day), and high (>30 mg/day) to guide monitoring intensity and side-effect anticipation 4.

• Aim to maintain chronic doses ≤7.5 mg/day whenever possible, as doses above this threshold are associated with markedly higher cumulative toxicity including osteoporosis, diabetes, and cardiovascular disease 3.

• In patients with diabetes, osteoporosis, glaucoma, or hypertension, even 2.5 mg/day requires heightened vigilance; assess whether a biologic DMARD could replace corticosteroid therapy entirely 3.

Thyroid Function Considerations

• Adjust prednisone dosage in patients with thyroid dysfunction, as metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients 1.

Pediatric Considerations

• Base prednisone dosing on body surface area (60 mg/m²/day) rather than weight (2 mg/kg/day) in children, as weight-based dosing provides significantly lower doses in children <30 kg and may result in subtherapeutic treatment 9.

• For children with significant weight excess, calculate the dose based on ideal body weight rather than actual weight 4.

Monitoring Schedule During Therapy

• Schedule follow-up visits every 4-8 weeks during the first year of therapy and every 8-12 weeks thereafter to assess disease control, monitor for side effects, and evaluate adrenal function 3.

• At each visit, obtain serum sodium and potassium to detect emerging electrolyte abnormalities 3.

• Monitor disease-specific markers (ESR, CRP, or condition-specific laboratory tests) to identify early relapse or inadequate disease control 3.